Improving outcomes for older patients receiving allogeneic transplants through exercise

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional pilot study aims to assess the feasibility of a supervised exercise program for older adults undergoing allogeneic hematopoietic cell transplantation (HCT). The study will enroll 60-72 participants who will be divided into two cohorts: one for prehabilitation before the transplant and another for rehabilitation after the transplant. The primary focus is to evaluate whether this exercise intervention can enhance recovery and overall outcomes for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Cohort A (Prehab)

1. Age 60 years or older.
2. Planned allogeneic HCT in the next 1-6 months.
3. Hematological malignancy as the indication for HCT.
4. Pre-frail or frail by Fried frailty phenotype.

Cohort B (Rehab)

1. Age 60 years or older.
2. Planned allogeneic HCT or HCT within the last 30 days.
3. Hematological malignancy as the indication for HCT.

Exclusion Criteria:

Cohorts A and B

1\. Comorbid disability or illness that prevents safe exercise.

Where it's running

• Penn Medicine
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Shannon McCurdy, MD — Penn Medicine
• Study coordinator: Jacqui Rick
• Email: Jacqui.Rick@pennmedicine.upenn.edu
• Phone: 2152209675

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating disparities in allogeneic transplantation based on ancestry and socio-economic status

  This study looks at how a patient's background and financial situation affect their choices and outcomes in bone marrow transplants at MD Anderson Cancer Center.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT06450353

• DNP-MRSI to predict HCC treatment response

  This study tests whether DNP-MRSI imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism in liver tumors can indicate which BCLC A–C HCC lesions will respond after locoregional therapies or systemic treatment.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07807475

• Pemefolacianine imaging for lung cancer surgery

  A first-in-human dose study tests a new fluorescent imaging agent given before lung cancer surgery to see if it is safe and helps highlight tissue during thoracoscopy or robotic surgery.

  Recruiting Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07772895

• Low Dose Radiotherapy for Osteoarthritis

  This study tests whether low-dose radiotherapy can help reduce pain and improve function for adults with osteoarthritis who have not benefited from standard treatments.

  Recruiting at 2 sites Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania and 1 other locations · NCT07715188

• TumorGlow use during surgery to see sarcoma lung metastases in children

  This pediatric study tests a single 5 mg/kg dose of TumorGlow (ICG) given before surgery to help doctors see sarcoma metastases in the lungs during tumor removal.

  Recruiting Early Phase 1 Abramson Cancer Center at Penn Medicine · Phildelphia, Pennsylvania · NCT07658768

• Lifestyle and energy balance in breast cancer survivorship

  This study tests how diet, physical activity, and urinary metabolites relate to lifestyle changes in women newly diagnosed with breast cancer during treatment and survivorship.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07655934

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.